Department of Clinical Sciences, Genomics, Diabetes and Endocrinology, Lund University Diabetes Centre, Lund University, Malmö, Sweden
Department of Clinical Sciences, Genomics, Diabetes and Endocrinology, Lund University Diabetes Centre, Lund University, Malmö, Sweden.
Diabetes. 2020 Oct;69(10):2086-2093. doi: 10.2337/dbi20-0001. Epub 2020 Aug 25.
Type 2 diabetes (T2D) is defined by a single metabolite, glucose, but is increasingly recognized as a highly heterogeneous disease, including individuals with varying clinical characteristics, disease progression, drug response, and risk of complications. Identification of subtypes with differing risk profiles and disease etiologies at diagnosis could open up avenues for personalized medicine and allow clinical resources to be focused to the patients who would be most likely to develop diabetic complications, thereby both improving patient health and reducing costs for the health sector. More homogeneous populations also offer increased power in experimental, genetic, and clinical studies. Clinical parameters are easily available and reflect relevant disease pathways, including the effects of both genetic and environmental exposures. We used six clinical parameters (GAD autoantibodies, age at diabetes onset, HbA, BMI, and measures of insulin resistance and insulin secretion) to cluster adult-onset diabetes patients into five subtypes. These subtypes have been robustly reproduced in several populations and associated with different risks of complications, comorbidities, genetics, and response to treatment. Importantly, the group with severe insulin-deficient diabetes (SIDD) had increased risk of retinopathy and neuropathy, whereas the severe insulin-resistant diabetes (SIRD) group had the highest risk for diabetic kidney disease (DKD) and fatty liver, emphasizing the importance of insulin resistance for DKD and hepatosteatosis in T2D. In conclusion, we believe that subclassification using these highly relevant parameters could provide a framework for personalized medicine in diabetes.
2 型糖尿病(T2D)由单一代谢物葡萄糖定义,但越来越被认为是一种高度异质性疾病,包括具有不同临床特征、疾病进展、药物反应和并发症风险的个体。在诊断时识别具有不同风险概况和疾病病因的亚型,可以为个体化医学开辟途径,并使临床资源集中在最有可能发展为糖尿病并发症的患者身上,从而改善患者的健康状况并降低卫生部门的成本。更同质的人群也为实验、遗传和临床研究提供了更大的优势。临床参数易于获得,反映了相关的疾病途径,包括遗传和环境暴露的影响。我们使用六个临床参数(GAD 自身抗体、糖尿病发病年龄、HbA、BMI 以及胰岛素抵抗和胰岛素分泌的测量值)将成年发病的糖尿病患者聚类为五个亚型。这些亚型在多个人群中得到了稳健的再现,并与并发症、合并症、遗传学和治疗反应的不同风险相关。重要的是,严重胰岛素缺乏性糖尿病(SIDD)组的视网膜病变和神经病变风险增加,而严重胰岛素抵抗性糖尿病(SIRD)组的糖尿病肾病(DKD)和脂肪肝风险最高,强调了胰岛素抵抗在 T2D 中对 DKD 和肝脂肪变性的重要性。总之,我们认为使用这些高度相关的参数进行分类可以为糖尿病的个体化医学提供一个框架。